Toward Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Comment on Ledziński et al. Personalized Medicine in Pulmonary Arterial Hypertension: Utilizing Artificial Intelligence for Death Prevention. J. Clin. Med. 2025, 14, 8325

迈向肺动脉高压临床可操作的可解释人工智能:终点、校准和外部验证。评述 Ledziński 等人的文章《肺动脉高压的个性化医疗:利用人工智能预防死亡》(J. Clin. Med. 2025, 14, 8325)。

阅读:2

Abstract

We read with great interest the recent contribution proposing a machine-learning model (XGBoost), developed using registry data, to estimate mortality risk in adult patients with pulmonary arterial hypertension (PAH) and incorporating an SHAP-based interpretability strategy to clarify, both globally and at the individual level, the determinants of the prediction [...].

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。